BURLINGAME, Calif.–(BUSINESS WIRE)– Ablexis, LLC announced today the expansion of the roster of licensees of its AlivaMab Mouse technology to include an additional top 15 pharmaceutical company. This perpetual, non-exclusive license provides the licensee with its own colony of AlivaMab Mouse and broad rights to use the AlivaMab Mouse for antibody drug discovery and development. Ablexis will receive an eight-figure up-front payment.
“Ablexis’ licensees are using the AlivaMab Mouse with impressive speed and efficiency to generate antibodies that meet target product profiles, including antibodies against traditionally difficult targets and with ultra-high potency of target modulation,” said Larry Green, Ph.D., Chief Executive Officer of Ablexis. “The reliability and ease of use of the AlivaMab Mouse relative to other next-generation transgenic and in vitro display platforms makes the AlivaMab Mouse a tremendously enabling technology for the rapid discovery and subsequent efficient development of therapeutic antibodies. As a result, the AlivaMab Mouse has emerged as the preferred platform for licensing by the world’s leading pharmaceutical companies that seek in-house implementation of a robust, broadly applicable technology for therapeutic antibody discovery.”